Skip to main content
Contact Us
Subscribe
E-Edition
75°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Candel Therapeutics, Inc. - Common Stock
(NQ:
CADL
)
7.940
-0.150 (-1.85%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Candel Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Today 16:15 EDT
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
February 25, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week
February 23, 2025
Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.
Via
Stocktwits
How Is The Market Feeling About Candel Therapeutics?
January 08, 2025
Via
Benzinga
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
February 20, 2025
Via
Benzinga
Major Indexes Falter; Dow Drops Over 550 Points
February 20, 2025
The Dow Jones Industrial Average is down 556 points midday, heading for its worst daily percentage loss since mid January, while the S&P 500 Index and Nasdaq Composite sit firmly in the red as well.
Via
Talk Markets
Topics
Stocks
Stocks / Equities
Exposures
US Equities
Let's uncover which stocks are experiencing notable gaps during today's session.
February 20, 2025
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.
Via
Chartmill
Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice
February 20, 2025
CAN-2409 could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst.
Via
Stocktwits
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
February 19, 2025
Via
Benzinga
Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call
February 07, 2025
The analyst noted that CAN-2409's early data in prostate cancer suggests the potential for a meaningful breakthrough, given the lack of significant advancements in available treatments.
Via
Stocktwits
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
February 07, 2025
Via
Benzinga
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
January 13, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
December 20, 2024
Via
Benzinga
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
December 16, 2024
From
Candel Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 13, 2024
Via
Benzinga
What's Going On With Candel Therapeutics Shares Friday?
December 13, 2024
Candel shares are moving lower on Friday after the company priced its $80 million underwritten public offering of shares and pre-funded warrants.
Via
Benzinga
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
December 13, 2024
Via
Benzinga
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
December 13, 2024
Via
Benzinga
Candel Therapeutics Announces Pricing of Public Offering
December 12, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces $80 Million Proposed Public Offering
December 12, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Shares Are Up Today: What's Going On?
December 12, 2024
Candel Therapeutics, Inc. (NASDAQ: CADL) shares are trading higher Thursday potentially driven by continued momentum following the company's announcement of positive phase 3 trial results for its...
Via
Benzinga
Gamestop, Adobe, Meta, Candel Therapeutics, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
December 11, 2024
The stock market experienced a wave of optimism on Wednesday, driven by the latest inflation report. The Nasdaq 100 surged 1.7%, achieving a new record high.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 11, 2024
Via
Benzinga
Crude Oil Jumps 2%; Macy's Lowers Earnings Forecast
December 11, 2024
Via
Benzinga
Exposures
Fossil Fuels
10 Health Care Stocks Whale Activity In Today's Session
December 11, 2024
Via
Benzinga
Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations
December 11, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Candel Therapeutics Stock Surges Over 100% - Here's Why
December 11, 2024
Candel Therapeutics reports phase 3 trial success for CAN-2409 in prostate cancer, showing improved disease-free survival and safety consistency.
Via
Benzinga
Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug
December 11, 2024
The company is hoping to eventually launch the first major new treatment for localized prostate cancer in over 20 years.
Via
Investor's Business Daily
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival
December 11, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 14, 2024
From
Candel Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.